Please join us for our next M3 Quarterly Refresher held August 11, 10am - 2pm EDT.
Click on the link below to register and choose from the drop-down menu the session you want to attend. Once registered, details of the webinar will be e-mailed to you.
Future sessions of the M3 Quarterly Refresher will be held:
November 10, 2016
February 9, 2017
May 11, 2017
With the upgrade of our GoToMeeting/GoToWebinar accounts, the MISTIE III Monthly Webinars have been recreated.
Please take a minute to re-register yourself for this important webinar.
Once registered details of the call will be e-mailed to you.
As of July's Monthly Webinar, old webinar links will NOT work.
The BIOS team at Johns Hopkins University is delighted to be a part of Edge Therapeutics' clinical trial Newton-2 (Protocol #EG-01-1962-03) evaluating a new treatment for certain patients with aneurysmal subarachnoid hemorrhage (aSAH). Our goal at BIOS will be to ensure that the blinded assessors at the clinical sites are well versed on the neurologic outcome assessments in this trial. Because the outcome on the GOSE rating scale is the primary endpoint in this study, it is imperative that the assessor has a thorough understanding of the survey methodology, including the ability to perform a thorough assessment of the extent of disability at baseline, prior to the aSAH. We are providing this online training course, assessment tools, and informational updates. Please see the menu for these materials.
Additionally, please feel free to contact us with any questions you may have. Meanwhile, we look forward to working with you!
CLEAR-III was all the talk at this year's International Stroke Conference (ISC). We had a number of presentations and posters discussing the Day-180 results of this six-year international multicenter trial exploring the delivery of alteplase, a thrombolytic ("clot buster"), via the extraventricular drain in patients with intraventricular hemorrhage (IVH). Thank you to all the clinical site staff and patients that contributed to this trial. There is alway more research needed when dealing with such a serious condition, but the knowledge gained on this project has been invaluable and will shape the future direction of future research for years to come.
Abstracts and Slides Dr. Hanley's presentation was LB12. Dr. Issam Awad's presentation was LB13
Additionally, there have been lots of new articles about the CLEAR III results: